- 學位論文
研究中藥複方JC001 抗胰臟癌之效用
The anti-pancreatic cancer effects of a herbal prescription JC001
摘要
胰腺癌 (Pancreatic cancer) 在全球都是極難治癒的疾病，因為胰臟癌初期症狀並不明顯，且胰臟位置與其他周邊器官重疊，造成在檢查上的困難性，往往當發現症狀時便已是癌症末期，且手術治療癒後普遍不佳，死亡風險很高。以往的治療主要以手術為主，化學治療及放射線治療為輔助，近年多種癌症免疫療法已被研發，藉由提升自體免疫力來增加病人生存機率，因此我們在此利用複方中草藥JC001想去看當在活體動物PDX-1-Cre , LSL-KRASG12D 轉殖基因老鼠上服用JC001時，老鼠癌症的症狀及病程是否有變化產生，以及老鼠體內的免疫功能所產生的變化。我們發現到在 7 週時老鼠胰臟重量及切片觀察胰臟癌化程度並未有顯著差異，而在 12 、24 、40 週齡時則發現在胰臟重量及切片觀察胰臟癌化程度，在餵食JC001的組別相較未餵食JC001的組別，胰臟重量較輕，切片上也可看出胰臟導管數量及纖維化程度比較低，在免疫組織染色Indoleamine 2,3-dioxygenase 1 (IDO-1) , T-cell immunoglobulin domain and mucin domain-3 (TIM-3), Proliferating cell nuclear antigen (PCNA) 上也可以觀察到12、40 週齡的老鼠在有餵食JC001的組別裡表現量較低，而7 週齡的組別在有餵食JC001的組別裡，部分表現量較低。而在上皮間質細胞轉化 (epithelial mesenchymal transition , EMT) 相關因子N-cadherin, alpha smooth muscle Actin (alpha-SMA), Snail Family Zinc Finger 1 (Snail-1), Zinc Finger E-Box Binding Homeobox 1 (ZEB-1)，也會因餵食JC001 而表現量明顯下調，由此可推論由於餵食JC001，老鼠癌症的程度因此改善，也許往後對於胰臟癌臨床應用上會是個更好的治療方法。
並列摘要
Pancreatic cancer is the one of the difficult disease in the world, because early pancreatic cancer symptoms are not obvious. Besides the space of pancreas have cover with others organs, It will increase the difficulty to check this disease. When the symptoms have found as it is terminal cancer, and it have very high risk to be death. Previous treatment mainly with surgery, chemotherapy and radiation therapy to fixed this problem. In recently years, many types of cancer immunotherapy have been developed to enhance autologous immunity to raise the patient’s survival percentage. For this research would like to understand when PDX-1-Cre , LSL-KRASG12D transgenic mice take compound chinese herbal medicine JC001 might have some changeable for mouse cancer symptoms, and their immune function in mice have changed. According the result, according to the 7 weeks old mouse pancreas weight and pathological section have shows pancreatic did not have significant difference. Research the mice in 12, 24, 40 weeks of age, the team did not have JC001, their pancreas weight were slight light with the group have JC001. From the pathological section can shows quantity pancreatic duct and the degree of fibrosis were lower. On the other hand, from Immunohistochemistry Indoleamine 2,3-dioxygenase 1 (IDO-1) , T-cell immunoglobulin domain and mucin domain-3 (TIM-3), Proliferating cell nuclear antigen (PCNA) can also be observed on 12, 40 week-old mice feed JC001 constituency were not significant difference. Besides, at 7 weeks of age group have feed JC001 constituency in the lower part of the performance amount. Epithelial mesenchymal transition, EMT related factors N-cadherin, alpha smooth muscle Actin (alpha-SMA), Snail Family Zinc Finger 1 (Snail-1), Zinc Finger E-Box Binding Homeobox 1 (ZEB-1) will reduces the performance for feeding JC001. Which is means feeding JC001 can help mice to reduce their symptoms. For the pancreatic cancer clinical application will be another choice to method of treatment.